TG Therapeutics (TGTX) Stock: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$55.27
-0.10 (-0.18%)
▼
5d:
+2.52%
30d:
+2.56%
90d:
+0.69%
BUY
MODERATE Confidence
Analysis Updated: Oct 12, 2026 12:00 AM ET
Earnings: Nov 02, 2026
19d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 7, 2026 at $52.95 · last confirmed Oct 8, 2026
Strength: 6.8/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TGTX shows positive signals but monitor for confirmation. Market pricing in 7.7% growth. Moderate conviction.
💡 BUY OPPORTUNITY: TGTX shows positive signals but monitor for confirmation. Market pricing in 7.7% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$85.96
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$53.37
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $55.27, which is considered fair relative to its 30-day fair value range of $53.85 to $56.91. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.4) compared to its historical average (16.3). At these levels, the market is pricing in 7.7% annual earnings growth.
Technical Outlook: Technically, TGTX is in a uptrend. Immediate support is located at $51.34, while resistance sits at $56.98.
Market Sentiment: TGTX scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $69.71 (+26.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TGTX is in a uptrend. Immediate support is located at $51.34, while resistance sits at $56.98.
Market Sentiment: TGTX scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $69.71 (+26.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$53.85 -
$56.91
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.1% below Wall St target ($69.71)
- BULLISH: Expecting earnings turnaround to 7.7% growth with 70.3% revenue growth
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$53.85 -
$56.91
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$51.34
Resistance Level
$56.98
Current Trend
Uptrend
Technical data as of
Oct 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.41
Wall Street Target
$69.71
(+26.1%)
Revenue Growth (YoY)
70.3%
Earnings Growth (YoY)
-70.6%
Profit Margin
55.2%
Valuation Premium vs History
+7.7% premium
PE vs Historical
20.4 vs 16.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.7%
(market-implied from PE analysis)
1-Year Target
$59.53
(+8%)
2-Year Target
$64.11
(+16%)
3-Year Target
$69.05
(+25%)
3-Yr Target (if PE normalizes)
(PE: 20→16)
PE COMPRESSION
$55.14
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 185.1%)
$186.54
(+238%)
Base:
(SPY PE: 19.9, Growth: 185.1%)
$181.51
(+228%)
Bear:
(PE: 16.3, Growth: 185.1%)
$148.97
(+170%)
📈
Valuation based on Current Earnings
Trailing PE: 20.13 | Current EPS (TTM): $2.75
Bull Case
$59.98
(+9%)
Analyst growth -1.5%, PE expands to 22.2
Base Case
$54.52
(-1%)
Market implied -1.5%, PE stable at 20.1
Bear Case
$37.65
(-32%)
Severe decline -20.0%, PE contracts to 17.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 13, 2026 4:31 AM ET
Data refreshes hourly during market hours. Next update: 5:31 AM
Data refreshes hourly during market hours. Next update: 5:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 64 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 73 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 59 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$146 | 73 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
14 analysts |
$107 | 67 BUY |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
